THE ASSOCIATION FOR CLINICAL GENOMIC SCIENCE
The promotion, encouragement and advancement of the study and practice of clinical genomic science.The advancement of education, research and innovation in clinical genomic science.The development and promotion of clinical standards in clinical genomic science.
Financial health, per its FY2024 accounts
The accounts state that the charity incurred a net deficit of £5,842 for the year ended 31 December 2024, resulting in unrestricted reserves falling to £111,361 from £117,203 the previous year. The trustees confirm that the charity is prepared on a going concern basis, believing that budgeted income and expenditure are sufficient to continue operations. No staff were employed during the year, and no trustees received remuneration.
What the accounts disclose
“The Charity acknowledges the volatility of its levels of generated income and its trustees have committed to setting aside an unrestricted reserve of £50,000” — page 5
Register events
- Received assets from another charity (23/04/2014)
Trustees
- David Moore
- John Short
- Rachael Ellis
Income and spending
| Financial year end | Income | Spending |
|---|---|---|
| 31/12/2024 | £70k | £76k |
| 31/12/2023 | £71k | £66k |
| 31/12/2022 | £86k | £59k |
| 31/12/2021 | £25k | £21k |
| 31/12/2020 | £18k | £40k |
Common questions
Is THE ASSOCIATION FOR CLINICAL GENOMIC SCIENCE financially healthy?
Per its FY2024 accounts: The accounts state that the charity incurred a net deficit of £5,842 for the year ended 31 December 2024, resulting in unrestricted reserves falling to £111,361 from £117,203 the previous year. The trustees confirm that the charity is prepared on a going concern basis, believing that budgeted income and expenditure are sufficient to continue operations. No staff were employed during the year, and no trustees received remuneration. Its FY2024 accounts were independently examined.